Erosive Arthritis and Hepatic Granuloma Formation Induced by Peptidoglycan Polysaccharide in Rats Is Aggravated by Prasugrel Treatment

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Garcia, Analia E ^a   Rico, Mario C ^a   Liverani, Elisabetta ^a   DeLa Cadena, Raul A ^a   Bray, Paul F ^b   Kunapuli, Satya P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDOGLYCAN POLYSACCHARIDE; PRASUGREL; RANTES; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; EROSIVE ARTHRITIS; EX VIVO STUDY; FEMALE; FIBROSIS; GIANT CELL; HEPATOMEGALY; LIVER GRANULOMA; MORPHOMETRICS; NEUTROPHIL COUNT; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; THROMBOCYTOSIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CYTOKINES; FEMALE; GRANULOMA; INFLAMMATION; JOINTS; LIVER; PEPTIDOGLYCAN; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRODRUGS; RATS; RATS, INBRED LEW; THIOPHENES; TICLOPIDINE;

ANIMALIA; MUS; RATTUS;

EID: 84879824693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069093     Document Type: Article

References (37)

1. Spinler SA, Rees C, (2009) Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm 15: 383-395.
2. Algaier I, Jakubowski JA, Asai F, von Kugelgen I, (2008) Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6: 1908-1914.
3. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F, (2005) Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31: 184-194.
4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM, (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.
5. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, et al. (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 4: 403-410.
6. Blauwet L, Matteson E, (2003) Acute inflammatory arthritis: an adverse effect of clopidogrel? J Clin Rheumatol 9: 128-129.
7. Boulman N, Rozenbaum M, Slobodin G, Rosner I, (2005) Acute polyarthritis associated with clopidogrel treatment. Isr Med Assoc J 7: 670-671.
8. Chen KK, Ginges I, Manolios N, (2003) Clopidogrel-associated acute arthritis. Intern Med J 33: 618-619.
9. Kanadiya MK, Singhal S, Koshal VB, (2011) Prasugrel as a safe alternative for clopidogrel-associated arthritis. J Invasive Cardiol 23: E137-138.
10. Kawashiri SY, Taguchi M, Kawakami A, Eguchi K (2009) Clopidogrel-associated acute arthritis. Rheumatol Int.
11. Khan EA, Blake JW, Stamp LK, (2009) Ticlopidine as a safe alternative for clopidogrel-associated arthritis. J Rheumatol 36: 855-856.
12. Muthusamy AS, Vaidya A, Friend PJ, (2006) Clopidogrel-associated acute migratory arthritis following kidney-pancreas transplantation. Int J Immunopathol Pharmacol 19: 443-444.
13. Tayyareci Y, (2008) Acute arthritis associated with loading dose of clopidogrel. J Clin Rheumatol 14: 254-255.
14. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, et al. (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327: 580-583.
15. Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP, (2011) Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One 6: e26035.
16. Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, et al. (2007) Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J Cell Physiol 211: 504-512.
17. DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, et al. (1991) Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol 260: G213-219.
18. Espinola RG, Uknis A, Sainz IM, Isordia-Salas I, Pixley R, et al. (2004) A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol 165: 969-976.
19. Koizumi F, Matsuno H, Wakaki K, Ishii Y, Kurashige Y, et al. (1999) Synovitis in rheumatoid arthritis: scoring of characteristic histopathological features. Pathol Int 49: 298-304.
20. Rooney M, Condell D, Quinlan W, Daly L, Whelan A, et al. (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31: 956-963.
21. Becker RC, Gurbel PA, (2010) Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 103: 535-544.
22. Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, et al. (2002) Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 46: 2857-2866.
23. Boilard E, Larabee K, Shnayder R, Jacobs K, Farndale RW, et al. (2011) Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol 186: 4361-4366.
24. Hsu J, Gu Y, Tan SL, Narula S, DeMartino JA, et al. (2013) Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol Lett 150: 97-104.
25. Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA, (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46: 1498-1503.
26. Sellam J, Proulle V, Jungel A, Ittah M, Miceli Richard C, et al. (2009) Increased levels of circulating microparticles in primary Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 11: R156.
27. Umekita K, Hidaka T, Ueno S, Takajo I, Kai Y, et al. (2009) Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. Mod Rheumatol 19: 265-272.
28. Barry OP, Pratico D, Savani RC, FitzGerald GA, (1998) Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 102: 136-144.
29. Kahner BN, Dorsam RT, Kunapuli SP, (2008) Role of P2Y receptor subtypes in platelet-derived microparticle generation. Front Biosci 13: 433-439.
30. Mosmann TR, (1994) Properties and functions of interleukin-10. Adv Immunol 56: 1-26.
31. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR, (1993) Interleukin-10. Annu Rev Immunol 11: 165-190.
32. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A, (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822.
33. Kochetkova I, Thornburg T, Callis G, Pascual DW, (2011) Segregated regulatory CD39+CD4+ T cell function: TGF-beta-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol 187: 4654-4666.
34. Wang L, Erling P, Bengtsson AA, Truedsson L, Sturfelt G, et al. (2004) Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus. J Thromb Haemost 2: 1436-1442.
35. Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M, (1990) Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 76: 336-344.
36. Wang L, Jacobsen SE, Bengtsson A, Erlinge D, (2004) P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 5: 16.
37. Liverani E, Rico MC, Garcia AE, Kilpatrick LE, Kunapuli SP, (2013) Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther 344: 231-243.